Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
VNRXthis companyVolitionRX Ltd	$0.20	-1.16×	-0.8×	15.8×	-1.9×	-2018.3%	100.0%	-1228.6%	-1352.2%	68.2%	1236.7%	-72.4%	-0.33×	-0.52×	-8.53×	0.17×	0.0%	3	-53.13	2	C
ALGSAligos Therapeutics, Inc.	$4.20	-3.8×	1.72×	42.14×	-3.45×	-97.0%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	1	-23.4	1	D+
BDSXBiodesix, Inc.	$10.70	-1.46×	-20.83×	0.58×	-4.79×	-2697.3%	81.1%	-31.4%	-39.8%	1430.6%	-38.9%	-46.1%	-29.56×	-2.45×	-3.6×	1.86×	0.0%	3	-6.48	1	D+
CTSOCytosorbents Corporation	$5.89	-4.92×	6.74×	1.07×	-14.38×	-1886.3%	71.5%	-38.4%	-22.1%	-138.9%	-38.8%	-31.5%	4.93×	-5.25×	-5.45×	2.13×	0.0%	4	-12.26	2	C
INMBINmune Bio, Inc.	$1.15	-0.84×	1.76×	829.46×	-0.39×	-34.6%	100.0%	-61738.0%	-91866.0%	-195.3%	-125.7%	-57.0%	0.04×	0.52×	0×	3.55×	0.0%	2	-10.59	2	C+
SKYESkye Bioscience, Inc.	$0.88	-0.53×	1.49×	0×	-0.44×	-12.5%	0.0%	0.0%	0.0%	-279.3%	-286.6%	-144.8%	0.01×	0.1×	0×	3.3×	0.0%	1	-41.6	2	C+
Peer median	—	-1.46×	1.72×	1.07×	-3.45×	-97.0%	71.5%	-38.4%	-39.8%	-138.9%	-123.9%	-57.0%	0.04×	0.1×	0×	3.3×	0.0%	2	-12.26	2	—